Table 2

Comparison of patient’s characteristics
AA-Amyloidosis Other renal p-value
(n=12) disease (n=12)
Age (years) 39.5 (32 – 44) 43.5 (33 – 48) 0.563
Male – n (%) 9 (75.0%) 6 (50%) 0.400
Self-reported time after initiation of IVDU (years) 22 (17 – 31) 19.5 (11 – 29) 0.418
Self-reported duration of IVDU (years) 20.5 (14 – 27) 12.5 (7 – 19) 0.056
History of opioid maintenance therapy 5 (41.7%) 7 (58.3%) 0.684
Chronic hepatitis B 1 (4.2%) 0 (0%) 1.0
Chronic hepatitis C 10 (83.3%) 11 (91.7%) 1.0
HIV 8 (66.7%) 2 (16.7%) 0.036
Medical history of
 Chronic or repeated skin infections 11 (91.7%) 6 (50.0%) 0.069
 Bacterial endocarditis 2 (16.7%) 1 (8.3%) 1.000
 Repeated pneumonia 8 (66.7%) 3 (25.0%) 0.100
Serum creatinine (mg/dl) 2.5 (1.9 – 4.0) 2.4 (1.7 – 3.2) 0.902
Proteinuria (g/24 h) 8.9 (7.5 – 19.1) 4.1 (1.5 – 9.8) 0.021
Serum albumin 2.2 (1.5 – 2.8) 3.0 (2.0 – 3.9) 0.124
Total serum protein 6.2 (5.3 – 7.2) 6.1 (4.9- 7.4) 0.853
Peripheral edema 3 (25.0%) 4 (33.3%) 1.0
Hypertension 1 (8.3%) 5 (60.0%) 0.1

Variables are expressed as median and interquartile-range (IQR) or as proportions as appropriate.

Jung et al.

Jung et al. BMC Nephrology 2012 13:151   doi:10.1186/1471-2369-13-151

Open Data